Last October, England’s drug-cost watchdogs dealt Eli Lilly a blow when they decreed that the company’s CDK 4/6 inhibitor to treat breast cancer, Verzenio, wasn’t cost-effective. So Lilly dished up a new price break—and now the National Institute for Health and Care Excellence (NICE) is on board. The problem, initially, was that Lilly couldn’t provide evidence that Verzenio… Read More »
At a recent medical conference a colleague asked me what I thought of breast implants. The reason for her question it turned out is that she had breast cancer and is thinking about having breast reconstruction. Should she have a breast implant as part of that? In the light of recent findings my answer was… Read More »
Metastatic breast cancer (MBC) can make patients feel isolated, and that’s the feeling Eisai is working to combat with its latest awareness campaign. The Japanese drugmaker has rolled out an initiative dubbed “FurtherMore,” which highlights the real-life stories of advanced breast cancer patients and “celebrates what can be achieved when they get the support they… Read More »
Women who like to wake up earlier have nearly half the risk of breast cancer as their night owl counterparts, according to a study presented by British scientists on Tuesday. Researchers at University of Bristol found that women who are “morning people” are 40 to 48 percent less likely to develop breast cancer than women… Read More »